Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer

J. Fucikova, M. Podrazil, L. Jarolim, P. Bilkova, M. Hensler, E. Becht, Z. Gasova, J. Klouckova, J. Kayserova, R. Horvath, A. Fialova, K. Vavrova, K. Sochorova, D. Rozkova, R. Spisek, J. Bartunkova,

. 2018 ; 67 (1) : 89-100. [pub] 20170925

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, fáze I, klinické zkoušky, fáze II, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001172

Grantová podpora
NV16-28135A MZ0 CEP - Centrální evidence projektů

OBJECTIVE: Immunotherapy of cancer has the potential to be effective mostly in patients with a low tumour burden. Rising PSA (prostate-specific antigen) levels in patients with prostate cancer represents such a situation. We performed the present clinical study with dendritic cell (DC)-based immunotherapy in this patient population. MATERIALS AND METHODS: The single-arm phase I/II trial registered as EudraCT 2009-017259-91 involved 27 patients with rising PSA levels. The study medication consisted of autologous DCs pulsed with the killed LNCaP cell line (DCVAC/PCa). Twelve patients with a favourable PSA response continued with the second cycle of immunotherapy. The primary and secondary objectives of the study were to assess the safety and determine the PSA doubling time (PSADT), respectively. RESULTS: No significant side effects were recorded. The median PSADT in all treated patients increased from 5.67 months prior to immunotherapy to 18.85 months after 12 doses (p < 0.0018). Twelve patients who continued immunotherapy with the second cycle had a median PSADT of 58 months that remained stable after the second cycle. In the peripheral blood, specific PSA-reacting T lymphocytes were increased significantly already after the fourth dose, and a stable frequency was detected throughout the remainder of DCVAC/PCa treatment. Long-term immunotherapy of prostate cancer patients experiencing early signs of PSA recurrence using DCVAC/PCa was safe, induced an immune response and led to the significant prolongation of PSADT. Long-term follow-up may show whether the changes in PSADT might improve the clinical outcome in patients with biochemical recurrence of the prostate cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001172
003      
CZ-PrNML
005      
20190115100932.0
007      
ta
008      
190107s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00262-017-2068-x $2 doi
035    __
$a (PubMed)28948333
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Fucikova, Jitka $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic. Sotio, Prague, Czech Republic.
245    10
$a Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer / $c J. Fucikova, M. Podrazil, L. Jarolim, P. Bilkova, M. Hensler, E. Becht, Z. Gasova, J. Klouckova, J. Kayserova, R. Horvath, A. Fialova, K. Vavrova, K. Sochorova, D. Rozkova, R. Spisek, J. Bartunkova,
520    9_
$a OBJECTIVE: Immunotherapy of cancer has the potential to be effective mostly in patients with a low tumour burden. Rising PSA (prostate-specific antigen) levels in patients with prostate cancer represents such a situation. We performed the present clinical study with dendritic cell (DC)-based immunotherapy in this patient population. MATERIALS AND METHODS: The single-arm phase I/II trial registered as EudraCT 2009-017259-91 involved 27 patients with rising PSA levels. The study medication consisted of autologous DCs pulsed with the killed LNCaP cell line (DCVAC/PCa). Twelve patients with a favourable PSA response continued with the second cycle of immunotherapy. The primary and secondary objectives of the study were to assess the safety and determine the PSA doubling time (PSADT), respectively. RESULTS: No significant side effects were recorded. The median PSADT in all treated patients increased from 5.67 months prior to immunotherapy to 18.85 months after 12 doses (p < 0.0018). Twelve patients who continued immunotherapy with the second cycle had a median PSADT of 58 months that remained stable after the second cycle. In the peripheral blood, specific PSA-reacting T lymphocytes were increased significantly already after the fourth dose, and a stable frequency was detected throughout the remainder of DCVAC/PCa treatment. Long-term immunotherapy of prostate cancer patients experiencing early signs of PSA recurrence using DCVAC/PCa was safe, induced an immune response and led to the significant prolongation of PSADT. Long-term follow-up may show whether the changes in PSADT might improve the clinical outcome in patients with biochemical recurrence of the prostate cancer.
650    _2
$a senioři $7 D000368
650    _2
$a dendritické buňky $x imunologie $x transplantace $7 D003713
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a počet lymfocytů $7 D018655
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prostatický specifický antigen $x genetika $x imunologie $x metabolismus $7 D017430
650    _2
$a prostatektomie $7 D011468
650    _2
$a nádory prostaty $x imunologie $x terapie $7 D011471
650    _2
$a radioterapie $7 D011878
650    _2
$a T-lymfocyty $x imunologie $7 D013601
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tumor burden $7 D047368
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Podrazil, Michal $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic.
700    1_
$a Jarolim, Ladislav $u Department of Urology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Bilkova, Pavla $u Sotio, Prague, Czech Republic.
700    1_
$a Hensler, Michal $u Sotio, Prague, Czech Republic.
700    1_
$a Becht, Etienne $u Laboratory 'Cancer, Immune Control and Escape', INSERM U1138, Cordeliers Research Centre, Paris, France. UMRS 1138, University Pierre and Marie Curie, Paris, France. UMRS 1138, University Paris Descartes, Paris, France.
700    1_
$a Gasova, Zdenka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Klouckova, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Kayserova, Jana $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic.
700    1_
$a Horvath, Rudolf $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic. Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Fialova, Anna $u Sotio, Prague, Czech Republic.
700    1_
$a Vavrova, Katerina $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic.
700    1_
$a Sochorova, Klara $u Sotio, Prague, Czech Republic.
700    1_
$a Rozkova, Daniela $u Sotio, Prague, Czech Republic.
700    1_
$a Spisek, Radek $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic. Sotio, Prague, Czech Republic.
700    1_
$a Bartunkova, Jirina $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, Prague 5, 15005, Prague, Czech Republic. jirina.bartunkova@lfmotol.cuni.cz. Sotio, Prague, Czech Republic. jirina.bartunkova@lfmotol.cuni.cz.
773    0_
$w MED00001041 $t Cancer immunology, immunotherapy CII $x 1432-0851 $g Roč. 67, č. 1 (2018), s. 89-100
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28948333 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190115101142 $b ABA008
999    __
$a ok $b bmc $g 1365079 $s 1039295
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 67 $c 1 $d 89-100 $e 20170925 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
GRA    __
$a NV16-28135A $p MZ0
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace